Clinical trials: Demyelinating Diseases
Vaccine-induced Thrombotic Thrombocytopenia Syndrome, Guillain-Barre Syndrome
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
This protocol proposes to investigate genetic factors that may be involved in the pathogenesis of adverse events of interest with selected covid-19 vaccines: vaccine-induced immune thrombotic thrombocytopenia, and neurological…
- Conditions
- Vaccine-induced Thrombotic Thrombocytopenia Syndrome, Guillain-Barre Syndrome, Acute Disseminated Encephalomyelitis, Transverse Myelitis
- Trial name
- NCT05630313
- Where
- Brazil
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Spinal Cord Injuries, Cerebral Palsy
LEAP a New Overground Body Weight Support Robot: Usability Trial
People with central nervous system disorders such as spinal cord injury, stroke, cerebral palsy, Parkinson's disease, multiple sclerosis, etc… often have impaired lower extremity function that limits activities of daily life and…
- Conditions
- Spinal Cord Injuries, Cerebral Palsy, Parkinson Disease, Multiple Sclerosis
- Trial name
- LEAP (NCT03458169)
- Testing
- Therapist LEAP session feedback, Participant LEAP session feedback, LEAP risk control validation
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Clinique Romande de Readaptation
Multiple Sclerosis
Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients
Serum neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) measured by single molecule array (SIMOA) are novel biomarkers of multiple sclerosis patients (MS) activity and progression.
- Trial name
- Nf-Ella Loca (NCT05352971)
- Testing
- Biomarker quantification
- Where
- 10 sites in France
- Volunteers
- 664 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis, Exposure During Pregnancy
Biogen Multiple Sclerosis Pregnancy Exposure Registry
The primary objective of the study is to prospectively evaluate pregnancy outcomes in women with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that…
- Trial name
- NCT01911767
- Testing
- Dimethyl fumarate, Peginterferon beta-1a
- Where
- 15 sites in United States, Australia and 8 more
- Volunteers
- 408 people
- Sponsor
- Biogen
NMO Spectrum Disorder, Azathioprine Adverse Reaction
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
Background: The pathogenesis of NMOSD has been linked to the cytokines interleukins (IL) -6, NOD-, LRR-and pyrin domain-containing 3 (NLRP3) and IL-18 that contribute to development of inflammatory reactionsmay.
- Trial name
- NCT05896605
- Testing
- Azathioprine
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Multiple Sclerosis, Clinically Isolated Syndrome
AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
The definition of the most 'at-risk' population within highly susceptible groups would provide an opportunity for preemptive therapeutics.
- Trial name
- ARMS (NCT00617383)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Disseminated Encephalomyelitis
ADAM'S Prognostic Markers
Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated demyelinating disorder of the central nervous system that predominantly affects children.
- Trial name
- NCT07188194
- Volunteers
- 32 people
- Sponsor
- Assiut University
Pain, Traumatic Brain Injury
The NRC Dataset. Developing a Minimum Dataset for Multidisciplinary Rehabilitation: a Modified E-Delphi Study
Several rehabilitation datasets are presently in use for specific patient groups in England. The 'National Clinical Audit of Specialist Rehabilitation for patients with complex needs following major injury' (NCASRI) evaluated…
- Conditions
- Pain, Traumatic Brain Injury, Major Trauma, Multiple Sclerosis
- Trial name
- NCT06726135
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ThomasCorbett
Multiple Sclerosis
Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS)
Multiple Sclerosis (MS) is most prevalent among women of childbearing age. The post-partum (PP) period is a critical phase in MS patients, during which a recrudescence of disease activity is expected.
- Trial name
- COPP-MS (NCT03917589)
- Where
- 5 sites in France
- Volunteers
- 350 people
- Sponsor
- Rennes University Hospital
Multiple Sclerosis
Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)
The treatment of multiple sclerosis was evolving in light of specific drug therapies to treat the disease, refinements and acceptance of imaging with MRI to diagnose and monitor the disease process, and progress in understanding…
- Trial name
- NCT00439257
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- US Department of Veterans Affairs
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Myelitis, Transverse, Neuromyelitis Optica
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
This multi-center randomized controlled trial evaluates if the addition of intravenous immunoglobulin to standard treatment of corticosteroids improves outcome in children and adults with first episode of Transverse Myelitis of…
- Trial name
- STRIVE (NCT02398994)
- Testing
- Intravenous Methylprednisolone, Intravenous Immunoglobulin
- Where
- 18 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Multiple Sclerosis, Relapsing-Remitting
Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood.
- Trial name
- BIO-MS (NCT06195800)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Ehlers-Danlos Syndrome, Multiple Sclerosis
Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)
The investigators propose that evidence of chronic cerebrospinal venous insufficiency (CCSVI) may be evident in the vasculature of the fundus.
- Trial name
- NCT01356134
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Genetic Disease Investigators
Multiple Sclerosis
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
The primary objective of the study is to evaluate the safety of natalizumab use in the pediatric multiple sclerosis (MS) population.
- Trial name
- NCT02137109
- Testing
- natalizumab
- Volunteers
- 400 people
- Sponsor
- Biogen
Multiple Sclerosis
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants who Have Participated in Cladribine Clinical Trials
- Trial name
- PREMIERE (NCT01013350)
- Where
- United States
- Volunteers
- 1,161 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon [IFN]-beta-1a) in children and adolescents, using information already recorded in medical records.
- Trial name
- REPLAY (NCT01207648)
- Testing
- Rebif®
- Where
- 18 sites in United States, Argentina and 6 more
- Volunteers
- 307 people
- Sponsor
- EMD Serono
Multiple Sclerosis (MS)
Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis
This single-center interventional study quasi-randomly allocated patients to a guided imagery or control intervention (positive journaling). Data were analyzed with treatment allocation masked.
- Trial name
- HLGI (NCT03177655)
- Testing
- Guided Imagery, Journaling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to <18 years with RRMS.
- Trial name
- Operetta III (NCT07503340)
- Testing
- Ocrelizumab co-formulated with rHuPH20
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche